NEW YORK, February 1, 2019 — Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, announced today the Company’s CEO Denis Corin will deliver a corporate presentation and conduct one-on-one meetings with investors and potential business partners at the BIO CEO & Investor Conference on February 11th -12th, 2019 in New York City. The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies.
Mr. Corin is scheduled to present at 3:00 PM on Monday, February 11th in the Chelsea room of the New York Marriott Marquis.
He will provide an update on the Company’s robust clinical pipeline including its FDA approved non-opioid drug Metastron, which relieves the severe pain associated with cancer that has metastasized to the bones. Metastron is expected to begin generating revenues for the Company in 2019.
About Q BioMed Inc.
Q BioMed aims to accelerate the monetization of biomedical technologies through rapid innovation and collaborative partnerships with industry leading researchers. Q BioMed believes its assets in oncology, vascular disease, and rare orphan diseases address unmet medical needs and large markets. The Company’s FDA approved, non-opioid drug Metastron, which relieves cancer bone pain, is expected to begin generating revenues in 2019. Metastron is also approved for sale in 21 other countries. In addition to treating pain, Metastron has shown evidence of treating the cancer itself and extending survival. Q BioMed plans to conduct Phase IV trials to support label extension and cancer survival benefit using Metastron.
For more information please visit www.qbiomed.com.
Forward-Looking Statements:
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Contact:
Denis Corin
CEO
Q BioMed Inc.
+1(646)884-7017
IR Contact
1 404 995 6671